« Return to News | Drug Sponsors

Linden Capital Partners to acquire SeraCare for $82 million

Monday, February 13, 2012 03:08 PM

SeraCare Life Sciences, a global life sciences company, has agreed to be acquired by an affiliate of Linden Capital Partners, a Chicago-based private equity firm that focuses on middle market leveraged buyout investments in the healthcare and life science industries.

Holders of outstanding shares of common stock of SeraCare will receive $4 per share, representing a 25% premium to the 30-day volume-weighted average stock price. SeraCare's board of directors unanimously approved the agreement.

“Linden is a natural strategic fit for SeraCare with a proven record of operating successful companies in the healthcare and life sciences sectors,” said Greg Gould, interim president, CEO and CFO. “Linden's acquisition of SeraCare recognizes our accomplishments and translates them into significant value for our shareholders.”

"SeraCare's product offerings, services and strong customer base provide an attractive foundation on which to compete and grow in the global high-growth markets of human diagnostics and therapeutics research and development," said Fran Lunger, a Linden Operating Partner and former CEO of Millipore.

If the merger is approved by shareholders, the transaction is expected to close in the second quarter of 2012.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.